Lower US life expectancy attributed to COVID-19, drug overdoses; suggestions to mask up lack teeth even as respiratory illnesses and hospitalizations spike; emergency department (ED) doctors look to curb private equity investments in staffing firms.
Seven months has been cut from the average American life expectancy, according to 2021 data from the CDC. NPR reported that 76.4 years is now the average life expectancy for a person born in the United States, marking the shortest life expectancy in almost 20 years. The 2 major contributors are COVID-19 and drug overdoses, particularly synthetic opioids such as fentanyl. For the second year in a row, COVID-19 is the third leading cause of death, even though deaths due to COVID-19 are decreasing. Mental health crises in young people have also contributed to the decline in life expectancy.
Despite the extreme increase in respiratory virus infections such as COVID-19, RSV, and the flu across the country, masking to reduce the spread have been heavily encouraged, but not required. The Washington Post reported that this is in part due to the polarization and politicism that is attached to the word “mandate” and the difficulty of justifying masking because of vaccine and antiviral availability. Public opinion on masking varies from that of individual choice and comfortability, to those that believe masking is a collective responsibility to protect the vulnerable. Currently, only about 30% of Americans report consistently masking when away from home, while 65% said they would “probably” mask if COVID-19 cases in their communities increase.
Emergency department (ED) providers and consumer advocates are seeking stronger enforcement of state laws that restrict the corporate ownership of medical practices, Kaiser Health News reported. Those wanting tougher enforcement are citing ED staffing companies backed by private-equity firms; the 2 largest are Envision Healthcare, owned by investment giant KKR & Co., and TeamHealth, owned by Blackstone. A federal lawsuit against Envision is scheduled to start in January 2024. The suit was filed by American Academy of Emergency Medicine Physician Group, which charges that Envision “uses shell business structures to retain de facto ownership of ER staffing groups, and it is asking the court to declare them illegal,” Kaiser said.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More